GTLLOTCRadio & Tv Broadcasting & Communications EquipmentUS GAAP · USD

Global Technologies LTD

Global Technologies Ltd. is a U.S.-based holding company that operates through subsidiaries focused on health and wellness distribution, advisory services, and a recently de-emphasized EV infrastructure venture. The company has been repositioning its portfolio toward consumer-facing pharmaceutical sales and related commercialization models while limiting further capital commitment to GOe3 and the EV charging sector.

Kysy yhtiöstä
Liikevaihto3,1milj. USD
+196,8 %v/v
Liikevoitto (EBIT)0,2milj. USD
+180,9 %v/v
EBIT-marginaali5,5%
+25,5 %-yks.v/v
Nettotulos−0,3milj. USD
−229,1 %v/v
Vapaa kassavirta0,4milj. USD
+1 016,0 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−101234milj. USD2020: 0,55 milj. USD2020: EBIT −0,23 milj. USD20202021: 0,02 milj. USD2021: EBIT −0,35 milj. USD20212022: 0,12 milj. USD2022: EBIT −0,50 milj. USD20222023: 0,02 milj. USD2023: EBIT −0,52 milj. USD20232024: 1,1 milj. USD2024: EBIT −0,21 milj. USD20242025: 3,1 milj. USD2025: EBIT 0,17 milj. USD20253,10,17
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Global Technologies LTD

Liiketoiminta

Osuus liikevaihdosta
Pharmaceutical supply and distribution45 %

Wholesale and distribution activities tied to pharmaceutical products and clinic-facing supply channels.

Sales agency and commissions20 %

Non-exclusive sales-agent arrangements that earn commissions by facilitating product sales.

Advisory and marketing services20 %

Consulting, marketing, and business development services delivered through GTLL Advisory.

Direct-to-consumer pharmaceutical commerce10 %

Emerging consumer-facing sales channel being built to replace paused wholesale GLP-1 activity.

EV infrastructure and other legacy initiatives5 %

GOe3-related EV charging and other legacy activities that are being deemphasized.

Asiakkaat

The company serves healthcare and wellness participants, including clinics, providers, partner pharmacies, and consumers reached through pharmaceutical sales channels. Its advisory business targets medical spas and wellness clinics, while its supply business depends on regulated pharmaceutical counterparties and channel partners. The pivot toward direct-to-consumer sales broadens the customer base but also increases dependence on consumer demand, compliance, and digital acquisition effectiveness.

Healthcare clinics and providers

Buy pharmaceutical products and related supply services for patient treatment and clinic operations.

Wellness clinics and medical spas

Purchase advisory, marketing, and commercialization support to attract patients and improve sales.

Partner pharmacies and pharmaceutical suppliers

Use the company as a sales and distribution intermediary to reach end customers and generate volume.

Direct consumers

Targeted for DTC pharmaceutical sales as the company shifts away from the paused wholesale channel.

Third-party contractors and channel partners

Support execution of sales, fulfillment, and profit-sharing arrangements across the platform.

Strategia

Management is reallocating resources toward sectors with clearer demand and monetization paths, especially consumer-facing pharmaceutical sales and related commercialization services. The company is also limiting further investment in GOe3 and EV infrastructure after concluding that the EV charging market is increasingly saturated and consolidating. Execution now depends on building compliant sales channels, monetizing customer data, and maintaining enough liquidity to fund the pivot.

Build a compliant direct-to-consumer pharmaceutical platformLyhyt aikaväli

The wholesale channel was disrupted by FDA-related rulings, so DTC is the main path to restore growth.

Monetize customer data and engagement capabilitiesKeskipitkä aikaväli

A data repository can improve targeting, conversion, and client outcomes across sales and advisory efforts.

Preserve capital and reduce exposure to EV infrastructureLyhyt aikaväli

GOe3 and the EV charging market appear less attractive due to saturation and consolidation.

Secure external funding and strategic partnershipsLyhyt aikaväli

The company has limited resources and needs financing to support operations and the pivot.

Maantiede

Global Technologies is incorporated in Delaware and operates from Greensboro, North Carolina, with a business footprint that is primarily U.S.-centric. The filings also reference broader macro exposure to the United States and other markets through supply chains, regulation, and capital markets, but no country revenue split is disclosed. Geography matters mainly because the company’s pharmaceutical activities are tied to U.S. FDA and state-level oversight, while geopolitical and supply-chain conditions can affect sourcing and customer demand.

Riskit

The company faces substantial going-concern and liquidity risk because it has limited financial resources, accumulated losses, and ongoing operating needs. Its business is also highly exposed to FDA, state healthcare, privacy, and data-security regulation, which can disrupt product availability or increase compliance costs. Competitive pressure, regulatory shifts around GLP-1 products, and dependence on successful execution of a new DTC model all create meaningful uncertainty.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Going-concern and liquidity shortfall1Competitive pressure from larger and better-capitalized rivals2Regulatory disruption in pharmaceutical sales3Macroeconomic and geopolitical uncertainty4Cybersecurity and data privacy exposure5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Going-concern and liquidity shortfallVaikutus: KriittinenTodennäköisyys: Korkea

    The company reports limited financial resources, accumulated deficit, and substantial doubt about its ability to continue.

    KohdistuuOperating fundingSupplier paymentsGrowth investment
  2. Competitive pressure from larger and better-capitalized rivalsVaikutus: KorkeaTodennäköisyys: Korkea

    Competitors may have stronger brands, broader networks, and more resources to win customers.

    KohdistuuDistributionAdvisoryWellness clinic channels
  3. Regulatory disruption in pharmaceutical salesVaikutus: KorkeaTodennäköisyys: Kohtalainen

    FDA and state oversight can pause or restrict product channels, as seen in the GLP-1 wholesale disruption.

    Kohdistuu: Primecare Supply and DTC pharmaceutical sales

  4. Macroeconomic and geopolitical uncertaintyVaikutus: KeskitasoTodennäköisyys: Korkea

    Inflation, supply-chain issues, and geopolitical tensions can slow spending and disrupt sourcing.

    KohdistuuCustomer demandSupplier availabilityCapital access
  5. Cybersecurity and data privacy exposureVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    The business relies on customer data, engagement systems, and sensitive healthcare-related information.

    KohdistuuMarketingCRMConsumer-facing sales operations
Kysy Clarifolta: Global Technologies LTD

Kirjanpito

Harkinnanvaraiset erät
Derivative liability valuation

The company reports gains and losses on derivative liabilities, so valuation inputs can materially move net income.

Vaikutus: Earnings volatility and balance sheet measurement

Restatement and acquisition accounting

Auditor procedures reference restated financials and GOe3 acquisition accounting, which require judgment on asset values and liabilities.

Vaikutus: Comparability and asset basis

Impairment and write-offs

Prepaid deposits, property and equipment, and intangible assets were written off, indicating recoverability assumptions matter.

Vaikutus: Asset values and operating results

Revenue recognition for commissions and profit-sharing

Sales-agent and operating agreements require careful assessment of principal-agent status and net vs gross presentation.

Vaikutus: Revenue and gross margin presentation

Going-concern assessment

Management and auditors highlight substantial doubt, making liquidity assumptions central to the financial statements.

Vaikutus: Disclosure risk and financing assumptions

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

GBT Technologies Inc.

GTCH · Services-Management Consulting Services

Elite Pharmaceuticals Inc /NV/

ELTP · Pharmaceutical Preparations

Global Innovative Platforms Inc.

GIPL · Surgical & Medical Instruments & Apparatus

Global Gas Corp

HGASW · Industrial Inorganic Chemicals

Greenway Technologies, Inc. & Subsidiaries

GWTI · Industrial Organic Chemicals

CTT Pharmaceutical Holdings, Inc.

CTTH · Pharmaceutical Preparations

Päivitetty: 24.9.2026